On May 21, 2019, Li, Jiarui; Xu, Ruyi; Cao, Qinyuan published a patent.HPLC of Formula: 16230-24-3 The title of the patent was Anti-tumor compound, and its preparation method and application in preparing drug for treating myelocytic leukemia. And the patent contained the following:
The invention relates to N-(3-((5-chloro-2-((4-((4-hydroxypiperidin-1-yl)methyl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)acrylamide I (named as BY4009) and its pharmaceutically acceptable salts (sulfate, pyrosulfate, etc.). Compound I was prepared starting from 1-(bromomethyl)-4-nitrobenzene, 4-hydroxypiperidine, and 3-nitroaniline by using benzylation, reduction, amidation and amination as the key steps. A pharmaceutical composition comprises the anti-tumor compound or its pharmaceutically acceptable salt, and pharmaceutically acceptable carrier. The pharmaceutical composition has application in preparing drug for treating tumor (myelocytic leukemia) by inhibiting BTK Tyrosine kinase phosphorylation. The anti-tumor compound has new mechanism of action, and is more effective. The experimental process involved the reaction of N-(3-Aminophenyl)acrylamide(cas: 16230-24-3).HPLC of Formula: 16230-24-3
The Article related to piperidinyl pyrimidinyl phenyl acrylamide preparation btk treatment myelocytic leukemia, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.HPLC of Formula: 16230-24-3
Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics